ASCO 2022 | UK genetic profiling to identify oncogenic drivers

Matthew Krebs, MBChB, MRCP, PhD, The Christie NHS Foundation Trust, Manchester, UK, discusses genomic profiling in the UK, including next generation sequencing (NGS) for genetic alteration associated with lung cancer including in EGFR, ALK, ROS and MET. Limitations to genomic profiling include the requirement of certain amount of tissue, as well as biopsy turnaround time. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.